Financial Gravity Asset Management, Inc. Kodiak Sciences Inc. Transaction History

Financial Gravity Asset Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$3.01 - $7.45 $0 - $0	0 New	0 $1,000
Q4 2023 Jun 26, 2024	BUY	$1.4 - $3.24 $0 - $0	0 New	0 $0
Q4 2023 Feb 15, 2024	BUY	$1.4 - $3.24 $0 - $0	0 New	0 $0
Q3 2023 Nov 15, 2023	SELL	$1.8 - $7.49 $12 - $52	-7 Closed	0 $0
Q2 2023 Aug 08, 2023	BUY	$4.3 - $9.48 $4 - $9	1 Added 16.67%	7 $5,000
Q1 2023 May 12, 2023	SELL	$4.81 - $8.88 $4 - $8	-1 Reduced 14.29%	6 $2,000
Q4 2022 Feb 15, 2023	SELL	$6.52 - $8.05 $110 - $136	-17 Reduced 70.83%	7 $5,000
Q3 2022 Nov 03, 2022	BUY	$7.57 - $12.5 $181 - $300	24 New	24 $3,000

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $455M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Financial Gravity Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Financial Gravity Asset Management, Inc. with notifications on news.